Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2015 4
2016 2
2018 3
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

11 results
Results by year

Citations

2 articles found by citation matching

Search results

Filters applied: . Clear all
Page 1
Thymosin beta 4 and the eye: the journey from bench to bedside.
Sosne G. Sosne G. Expert Opin Biol Ther. 2018 Jul;18(sup1):99-104. doi: 10.1080/14712598.2018.1486818. Expert Opin Biol Ther. 2018. PMID: 30063853 Review.
Thymosin beta 4 (Tbeta4) has important applications in ocular repair and Phase 3 clinical trials using Tbeta4 to treat dry eye and neurotrophic keratopathy are currently ongoing. ...Expert opinion: The electrifying possibility of Tbeta4 as a rev
Thymosin beta 4 (Tbeta4) has important applications in ocular repair and Phase 3 clinical trials using Tbeta4 to treat
Thymosin Beta 4: A Potential Novel Therapy for Neurotrophic Keratopathy, Dry Eye, and Ocular Surface Diseases.
Sosne G, Rimmer D, Kleinman HK, Ousler G. Sosne G, et al. Vitam Horm. 2016;102:277-306. doi: 10.1016/bs.vh.2016.04.012. Epub 2016 Jul 5. Vitam Horm. 2016. PMID: 27450739 Review.
Chronic ocular surface diseases such as dry eye, blepharitis, and neurotrophic keratopathies represent a significant and a growing therapeutic challenge. ...A focus on treatments that reduce the inflammatory responses while accelerating corneal epithelial growth wou …
Chronic ocular surface diseases such as dry eye, blepharitis, and neurotrophic keratopathies represent a significant and a gro …
Thymosin β4 and β10 in Sjögren's syndrome: saliva proteomics and minor salivary glands expression.
Bosello S, Peluso G, Iavarone F, Tolusso B, Messana I, Faa G, Castagnola M, Ferraccioli G. Bosello S, et al. Arthritis Res Ther. 2016 Oct 6;18(1):229. doi: 10.1186/s13075-016-1134-7. Arthritis Res Ther. 2016. PMID: 27716395 Free PMC article.
BACKGROUND: In the present study, we investigated whether thymosin beta (Tbeta) in saliva and in minor salivary glands is differentially expressed in patients with primary Sjogren's syndrome (pSS) and patients with autoimmune diseases (systemic sclerosis [SSc], syst …
BACKGROUND: In the present study, we investigated whether thymosin beta (Tbeta) in saliva and in minor salivary glands is diff …
Thymosin β4: a potential novel dry eye therapy.
Sosne G, Qiu P, Ousler GW 3rd, Dunn SP, Crockford D. Sosne G, et al. Ann N Y Acad Sci. 2012 Oct;1270:45-50. doi: 10.1111/j.1749-6632.2012.06682.x. Ann N Y Acad Sci. 2012. PMID: 23050816 Review.
The purpose of this manuscript is to review the clinical entity of dry eye syndrome (DES) and to provide a scientific basis and rationale for the usage of thymosin beta 4 (Tbeta4) as a novel therapy for DES. ...Based on previous studies, there i …
The purpose of this manuscript is to review the clinical entity of dry eye syndrome (DES) and to provide a scientific basis an …
Primary Mechanisms of Thymosin β4 Repair Activity in Dry Eye Disorders and Other Tissue Injuries.
Sosne G, Kleinman HK. Sosne G, et al. Invest Ophthalmol Vis Sci. 2015 Aug;56(9):5110-7. doi: 10.1167/iovs.15-16890. Invest Ophthalmol Vis Sci. 2015. PMID: 26241398 Review.
Dry eye disorders are becoming more common due to many causes, including an aging population, increased pollution, and postrefractive surgery. ...We will also speculate on additional mechanisms that might promote eye repair based on data from other tissue inj
Dry eye disorders are becoming more common due to many causes, including an aging population, increased pollution, and postref
Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model.
Sosne G, Ousler GW. Sosne G, et al. Clin Ophthalmol. 2015 May 20;9:877-84. doi: 10.2147/OPTH.S80954. eCollection 2015. Clin Ophthalmol. 2015. PMID: 26056426 Free PMC article.
BACKGROUND: The purpose of this study was to evaluate the safety and efficacy of thymosin beta 4 ophthalmic solution (RGN-259; Tbeta4) in subjects with moderate to severe dry eye using the CAE model. ...CONCLUSION: This study confirms the effica …
BACKGROUND: The purpose of this study was to evaluate the safety and efficacy of thymosin beta 4 ophthalmic solution (R …
Recombinant Human Thymosin β4 (rhTβ4) Modulates the Anti-Inflammatory Responses to Alleviate Benzalkonium Chloride (BAC)-Induced Dry Eye Disease.
Zhai Y, Zheng X, Mao Y, Li K, Liu Y, Gao Y, Zhao M, Yang R, Yu R, Chen W. Zhai Y, et al. Int J Mol Sci. 2022 May 13;23(10):5458. doi: 10.3390/ijms23105458. Int J Mol Sci. 2022. PMID: 35628276 Free PMC article.
Dry eye disease (DED) is a multifactorial ocular disorder that interferes with daily living and reduces quality of life. ...Eye drops consisting of 0.05% and 0.1% rhTbeta4 were used for treatment of DED. ...
Dry eye disease (DED) is a multifactorial ocular disorder that interferes with daily living and reduces quality of life. ...
Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial.
Sosne G, Dunn SP, Kim C. Sosne G, et al. Cornea. 2015 May;34(5):491-6. doi: 10.1097/ICO.0000000000000379. Cornea. 2015. PMID: 25826322 Clinical Trial.
PURPOSE: Standard therapies for severe dry eye are limited and fail to resolve the problem. The purpose of this study was to evaluate the safety and efficacy of Thymosin beta4 eye drops (RGN-259) as a novel therapy for severe dry eye dise …
PURPOSE: Standard therapies for severe dry eye are limited and fail to resolve the problem. The purpose of this study was to e …
Thymosin β4 significantly reduces the signs of dryness in a murine controlled adverse environment model of experimental dry eye.
Sosne G, Kim C, Kleinman HK. Sosne G, et al. Expert Opin Biol Ther. 2015;15 Suppl 1:S155-61. doi: 10.1517/14712598.2015.1019858. Epub 2015 Jun 22. Expert Opin Biol Ther. 2015. PMID: 26096547
OBJECTIVE: Dry eye syndrome is a common condition that affects up to 20% of the population aged 45 and older. ...The goal of this research was to determine the efficacy of various doses and the optimal frequency of thymosin beta4 (Tbeta4) treatment in a murin …
OBJECTIVE: Dry eye syndrome is a common condition that affects up to 20% of the population aged 45 and older. ...The goal of t …
RGN-259 (thymosin β4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model.
Kim CE, Kleinman HK, Sosne G, Ousler GW, Kim K, Kang S, Yang J. Kim CE, et al. Sci Rep. 2018 Jul 12;8(1):10500. doi: 10.1038/s41598-018-28861-5. Sci Rep. 2018. PMID: 30002412 Free PMC article.
This study evaluated the clinical activity of RGN-259 (thymosin beta4) in comparison with cyclosporine A (CsA), diquafosol (DQS), and lifitegrast (LFA) in a murine model of dry eye. ...In conclusion, RGN-259 promoted recovery of mucins and goblet cells, impro …
This study evaluated the clinical activity of RGN-259 (thymosin beta4) in comparison with cyclosporine A (CsA), diquafosol (DQS), and …
11 results